VZV T cell-mediated immunity.

Area of Science:

• Immunology
• Virology
• Vaccinology

Background:

• Primary varicella-zoster virus (VZV) infection, or chickenpox, establishes VZV-specific antibody and T cell-mediated immunity.
• T cell-mediated immunity, involving CD4 and CD8 effector and memory cells, is vital for chickenpox recovery and maintaining latent VZV.
• Declining VZV immunity, due to aging or immunosuppression, can lead to VZV reactivation, causing herpes zoster (shingles).

Purpose of the Study:

• To elucidate the role of VZV-specific immune responses in varicella recovery, VZV latency, and herpes zoster pathogenesis.
• To highlight the importance of T cell-mediated immunity in preventing VZV reactivation and managing zoster-associated pain.
• To emphasize the immunogenic benefits of VZV vaccines in boosting protective responses.

Main Methods:

• The abstract describes established immunological principles and clinical observations regarding VZV infection and vaccination.
• It synthesizes information on the development, function, and decline of VZV-specific humoral and cellular immunity.
• The text infers correlations between immune status and clinical outcomes like herpes zoster incidence and pain severity.

Main Results:

• Both primary VZV infection and varicella vaccination induce VZV-specific antibody and T cell-mediated immunity.
• Memory cell responses contribute to protection against VZV re-exposure and are boosted by environmental or endogenous stimuli.
• Declining VZV-specific T cell immunity is linked to VZV reactivation (herpes zoster) and zoster-associated pain severity.

Conclusions:

• VZV-specific T cell-mediated immunity is essential for controlling VZV infection, maintaining latency, and preventing reactivation.
• The VZV vaccine enhances these crucial immune responses, offering protection against herpes zoster.
• Boosting VZV immunity is key to managing latent virus and mitigating the impact of VZV reactivation.